Please login to the form below

Not currently logged in
Email:
Password:

Indian court rejects Novartis patent demand

A court in the Indian city of Chennai has rejected a claim by the Swiss pharmaceutical company Novartis regarding its cancer drug, Glivec (imatinib).

A court in the Indian city of Chennai has rejected a claim by the Swiss pharmaceutical company Novartis regarding its cancer drug, Glivec (imatinib).

Novartis was demanding that India grant a patent for Glivec to prevent cheap copies being made. The government in New Delhi opposed the move, saying that granting such a patent would violate India's patent legislation.

Novartis has been seeking a patent for Glivec in India, challenging the Indian patent law which currently does not protect incremental innovation. Indian law does not grant patents for modifications to old medicines, but only to properly innovative drugs developed after 1995.

6th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics